Novel anelgesic combination

Abstract

The invention discloses a method of administering a pharmaceutical combination comprising an NSAID and a slow release tramadol to a mammal in need of thereof. This invention further discloses an analgesic combination comprising an NSAID and a slow release tramadol for treating pain and pain related conditions.

Description

FIELD OF THE INVENTION [0001] The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of an NSAID and a slow release tramadol combination. The present invention further a pharmaceutical composition comprises of a slow release Tramadol and an immediate release NSAID such as Naproxen BACKGROUND OF THE INVENTION [0002] Tramadol (FORMULA 1) is a centrally acting synthetic opioid analgesic. It is chemically (±) cis-2-[(dimethylamino) methyl]-1-(3-methoxyphenyl)cyclo-hexanol hydrochloride. It is commercially available in form of its hydrochloride salt (Formula II) as Ultram tablets. Tramadol is indicated in the treatment of the management of moderate to moderately severe pain in adults. [0003] Tramadol is not an NSAID and doesn't have the increased risk of stomach ulceration and internal bleeding associated with non-steroidal anti inflammatory drugs (NSAID). However, it still ha...

AI Technical Summary

Benefits of technology

[0037] One object of the present invention is to provide methods, which can effectively be used in the treatment of pain and pain related diseases wherein the methods comprise administration of a therapeutically effective amount of an NSAID such as naproxen and administration of a therapeutically effective amount of a slow release Tramadol to a patient in need thereof.

[0053] The term “candidate for sustained release” encompasses all the characteristics of a drug which make it a candidate for formulating it into an extended release fashion like a short elimination half life and consequent dosing of more than once a day, a single dose product given in an extended fashion to achieve better clinical results and avoid side effects associated with an immediate release etc

Problems solved by technology

However, it still has certain commonly reported side effects include nausea, constipation, dizziness, headache, drowsiness, and vomiting.

Most anti-inflammatory drugs have been associated with an increased risk of serious upper gastrointestinal complications.

When given at a dose of 50 mg by rapid i.v. injection, tramadol may produce certain side effects unique to tramadol including hot flushes and sweating.

They, however, produce undesirable side effects and as a result cannot always be given repeatedly or at high doses.

In addition, ibuprofen, aspirin and some other NSAIDs may cause gastrointestinal side effects especially if used repeatedly.

The prior art, however, does not disclose a pharmaceutical composition comprising a slow release tramadol and an NSAID for treating a patient in need there of.

Further prior art doesn't disclose a method of treating pain or pain related disorder comprising a method of administering to a mammal in need thereof, a pharmaceutical composition comprising a slow release tramadol and an NSAID

Images